{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:41Z","timestamp":1790880701809,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The authors acknowledge the financial support received from the Researchers Supporting Project, King Saud University, Riyadh, Saudi Arabia.","award":["(RSP2023R16)"],"award-info":[{"award-number":["(RSP2023R16)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most common. Treatment, which has no definitive cure, aims for complete resolution of skin symptoms and depends on disease extent, severity, and impact on patients\u2019 lives. Biologics are an emerging treatment for psoriasis, targeting specific inflammatory pathways for potentially safer, more effective outcomes. However, these come with significant costs, necessitating more research to ensure value for money. This study aimed to compare the effectiveness of Risankizumab versus Adalimumab, the most commonly utilized biologic for managing psoriasis in Saudi Arabia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study retrospectively compared the effectiveness and direct medical cost of Risankizumab and Adalimumab in treating chronic plaque psoriasis in adults from two Saudi Arabian healthcare centers. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) were used to assess treatment effectiveness, with patient data sourced from electronic medical records. Multiple regression analysis was performed to examine various factors affecting treatment outcomes. An economic evaluation was conducted to examine the cost-effectiveness of the two drugs, considering four scenarios with varying dosage patterns and costs. Analysis was performed from the perspective of public healthcare payers and considered all utilized health services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The data for\u00a070 patients were analyzed, with comparable baseline characteristics between groups. While Risankizumab led to a greater reduction in PASI scores and BSA affected, these results were not statistically significant. The annual treatment cost for Risankizumab was higher than Adalimumab. Various scenarios were studied, considering real acquisition costs, double dosing for Adalimumab, and the use of biosimilars. A scenario assuming double dosing for Adalimumab and a 40% discount for Risankizumab demonstrated both cost and efficacy advantages in 71.25% of cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study compared the effectiveness and cost of Risankizumab and Adalimumab for treating chronic plaque psoriasis in Saudi Arabian hospitals. Although Risankizumab showed a greater reduction in symptoms, the difference was not statistically significant. However, under certain scenarios, Risankizumab demonstrated cost and efficacy advantages. These findings may influence treatment decisions for psoriasis, but further research is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12962-023-00504-1","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T01:01:48Z","timestamp":1702083708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia"],"prefix":"10.1186","volume":"21","author":[{"given":"Yazed","family":"AlRuthia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almaha H.","family":"Alfakhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtisam","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi Ali","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miteb A.","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Abdulrahman","family":"Alrabiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar Abdulrazzag","family":"Alsouan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Abdullah","family":"Alshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed Ali","family":"Almasaoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"issue":"5","key":"504_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IM Bronckers","year":"2015","unstructured":"Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373\u201384. https:\/\/doi.org\/10.1007\/s40272-015-0137-1. PMID: 26072040; PMCID: PMC4744260.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"504_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854. Epub 2016 Aug 30. PMID: 27573025.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"504_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","volume":"59","author":"S AlQassimi","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566\u201371. https:\/\/doi.org\/10.1111\/ijd.14864. Epub 2020 Apr 6. PMID: 32250451.","journal-title":"Int J Dermatol"},{"issue":"11","key":"504_CR4","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.19082\/5793","volume":"9","author":"AS Alhomoud","year":"2017","unstructured":"Alhomoud AS, Alnemer KA, Aldokheal MI, Alsultan AM, Alzahrani ZK. The prevalence of Cardiovascular Diseases risk factors associated with psoriasis in Saudi Arabia. Electron Physician. 2017;9(11):5793\u20139. https:\/\/doi.org\/10.19082\/5793. PMID: 29403621; PMCID: PMC5783130.","journal-title":"Electron Physician"},{"key":"504_CR5","doi-asserted-by":"publisher","unstructured":"Al Shobaili HA. The pattern of Skin Diseases in the Qassim region of Saudi Arabia: what the primary care physician should know. Ann Saudi Med. 2010 Nov-Dec;30(6):448\u201353. https:\/\/doi.org\/10.4103\/0256-4947.72263. PMID: 21060156; PMCID: PMC2994160.","DOI":"10.4103\/0256-4947.72263"},{"key":"504_CR6","doi-asserted-by":"publisher","unstructured":"Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015 Jan-Feb;90(1):9\u201320. https:\/\/doi.org\/10.1590\/abd1806-4841.20153038. PMID: 25672294; PMCID: PMC4323693.","DOI":"10.1590\/abd1806-4841.20153038"},{"issue":"4","key":"504_CR7","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385. PMID: 28404701; PMCID: PMC5389757.","journal-title":"Can Fam Physician"},{"issue":"9997","key":"504_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Sch\u00f6n MP, Psoriasis. 10.1016\/S0140-6736(14)61909-7. Lancet. 2015;386(9997):983\u201394. Epub 2015 May 27. PMID.","journal-title":"Lancet"},{"issue":"1","key":"504_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A, International Psoriasis Council Board Members and Councilors. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322. Epub 2019 Aug 16. PMID: 31425723.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"504_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daud\u00e9n E, Gisondi P, Iversen L, Kem\u00e9ny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310. https:\/\/doi.org\/10.1007\/s00403-010-1080-1. Epub 2010 Sep 21. PMID: 20857129; PMCID: PMC3016217.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"504_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","volume":"28","author":"M Abrouk","year":"2017","unstructured":"Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017;28(6):488\u201391. Epub 2017 Jan 18. PMID: 28042711.","journal-title":"J Dermatolog Treat"},{"key":"504_CR12","doi-asserted-by":"publisher","unstructured":"Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859\u2009\u2013\u200966. https:\/\/doi.org\/10.1016\/j.jaad.2003.09.014. PMID: 15153885.","DOI":"10.1016\/j.jaad.2003.09.014"},{"key":"504_CR13","doi-asserted-by":"publisher","unstructured":"Kaushik SB, Lebwohl MG, Psoriasis. Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057. Epub 2018 Jul 11. PMID: 30017705.","DOI":"10.1016\/j.jaad.2018.06.057"},{"issue":"6","key":"504_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. https:\/\/doi.org\/10.3390\/ijms20061475. PMID: 30909615; PMCID: PMC6471628.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"504_CR15","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. Epub 2019 Feb 13. PMID: 30772098.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"504_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1586\/14737167.2014.933671","volume":"14","author":"SR Feldman","year":"2014","unstructured":"Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):685\u2013705. Epub 2014 Jul 23. PMID: 25052261.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"504_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","volume":"107","author":"R Burgos-Pol","year":"2016","unstructured":"Burgos-Pol R, Mart\u00ednez-Sesmero JM, Ventura-Cerd\u00e1 JM, El\u00edas I, Caloto MT, Casado M\u00c1. The cost of Psoriasis and Psoriatic Arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016;107(7):577\u201390. https:\/\/doi.org\/10.1016\/j.ad.2016.04.018. English, Spanish.","journal-title":"Actas Dermosifiliogr"},{"key":"504_CR18","doi-asserted-by":"publisher","unstructured":"Kim IH, West CE, Kwatra SG, Feldman SR, O\u2019Neill JL. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol. 2012;13(6):365\u2009\u2013\u200974. https:\/\/doi.org\/10.2165\/11633110-000000000-00000. PMID: 22967166.","DOI":"10.2165\/11633110-000000000-00000"},{"issue":"6","key":"504_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","volume":"29","author":"J Bilal","year":"2018","unstructured":"Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat. 2018;29(6):569\u201378. Epub 2018 Mar 28. PMID: 29532693.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"504_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, Rasmussen MK, Skov L. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509\u201319. https:\/\/doi.org\/10.1111\/bjd.16102. Epub 2018 Jan 9. PMID: 29094341.","journal-title":"Br J Dermatol"},{"issue":"8","key":"504_CR21","doi-asserted-by":"publisher","first-page":"e0220868","DOI":"10.1371\/journal.pone.0220868","volume":"14","author":"LM Sawyer","year":"2019","unstructured":"Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, Borg E, Warren RB. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLoS ONE. 2019;14(8):e0220868. https:\/\/doi.org\/10.1371\/journal.pone.0220868. PMID: 31412060; PMCID: PMC6693782.","journal-title":"PLoS ONE"},{"issue":"4","key":"504_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.19325","volume":"183","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183(4):638\u201349. https:\/\/doi.org\/10.1111\/bjd.19325. Epub 2020 Aug 9. PMID: 32562551.","journal-title":"Br J Dermatol"},{"issue":"4","key":"504_CR23","doi-asserted-by":"publisher","first-page":"e13802","DOI":"10.1111\/dth.13802","volume":"33","author":"J Shi","year":"2020","unstructured":"Shi J, Xu J, Chen Y. A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted Drugs in the treatment of moderate to severe psoriasis. Dermatol Ther. 2020;33(4):e13802. https:\/\/doi.org\/10.1111\/dth.13802. Epub 2020 Jul 8. PMID: 32521069.","journal-title":"Dermatol Ther"},{"key":"504_CR24","doi-asserted-by":"publisher","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with Adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u2013586. https:\/\/doi.org\/10.1016\/S0140-6736(19)30952-3. Epub 2019 Jul 4. Erratum in: Lancet. 2019;: PMID: 31280967.","DOI":"10.1016\/S0140-6736(19)30952-3"},{"issue":"10148","key":"504_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of Risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6. Epub 2018 Aug 7. PMID: 30097359.","journal-title":"Lancet"},{"issue":"1","key":"504_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C. Efficacy and safety of Risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139. https:\/\/doi.org\/10.1111\/bjd.19341. Epub 2020 Sep 6. PMID: 32594522; PMCID: PMC7983954.","journal-title":"Br J Dermatol"},{"issue":"1","key":"504_CR27","doi-asserted-by":"publisher","first-page":"e14487","DOI":"10.1111\/dth.14487","volume":"34","author":"S Singh","year":"2021","unstructured":"Singh S, Singh S, Thangaswamy A, Thangaraju P, Varthya SB. Efficacy and safety of Risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis. Dermatol Ther. 2021;34(1):e14487. https:\/\/doi.org\/10.1111\/dth.14487. Epub 2020 Nov 14. PMID: 33140468.","journal-title":"Dermatol Ther"},{"key":"504_CR28","doi-asserted-by":"publisher","unstructured":"McKeage K, Duggan S, Risankizumab. First Global Approval. Drugs. 2019;79(8):893\u2013900. https:\/\/doi.org\/10.1007\/s40265-019-01136-7. PMID: 31098898.","DOI":"10.1007\/s40265-019-01136-7"},{"issue":"1\u20132","key":"504_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000488586","volume":"234","author":"A Costanzo","year":"2018","unstructured":"Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, Galeone C. Effectiveness end points in real-World studies on Biological therapies in Psoriasis: systematic review with Focus on Drug Survival. Dermatology. 2018;234(1\u20132):1\u201312. Epub 2018 May 15. PMID: 30300876.","journal-title":"Dermatology"},{"issue":"5","key":"504_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","volume":"74","author":"BE Strober","year":"2016","unstructured":"Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl MG. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74(5):851\u201361e4. Epub 2016 Feb 4. PMID: 26853180.","journal-title":"J Am Acad Dermatol"},{"key":"504_CR31","unstructured":"Fatani MI, Hamadah IR, Alajlan MA, Binamer Y, Alharbi AH, Alruwaili AF, Aldayel MA, Alenzi KA, Mubarki SM, Khardaly AM, Alomari BA. Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). Journal of Dermatological Treatment."},{"key":"504_CR32","doi-asserted-by":"publisher","unstructured":"Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician\u2019s Global Assessment. J Am Acad Dermatol. 2004;51(4):563-9. https:\/\/doi.org\/10.1016\/j.jaad.2004.04.012. PMID: 15389191.","DOI":"10.1016\/j.jaad.2004.04.012"},{"issue":"9","key":"504_CR33","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/jid.2012.124","volume":"132","author":"PA Gourraud","year":"2012","unstructured":"Gourraud PA, Le Gall C, Puzenat E, Aubin F, Ortonne JP, Paul CF. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol. 2012;132(9):2171\u20135. https:\/\/doi.org\/10.1038\/jid.2012.124. Epub 2012 May 17. PMID: 22592157.","journal-title":"J Invest Dermatol"},{"key":"504_CR34","doi-asserted-by":"publisher","unstructured":"Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pit\u00e0 O, Pezza M, Agostino D, Vernaci M, Miracapillo R, Valenti A, Cassano G. N. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):227\u2009\u2013\u200933. https:\/\/doi.org\/10.1177\/039463200902200125. PMID: 19309570.","DOI":"10.1177\/039463200902200125"},{"issue":"3","key":"504_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","volume":"19","author":"C Ryan","year":"2018","unstructured":"Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: focus on patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018;19(3):437\u201347. https:\/\/doi.org\/10.1007\/s40257-017-0341-6. PMID: 29380251; PMCID: PMC5945711.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"504_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09546634.2020.1744505","volume":"33","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ishii K, Joshi A, Bensimon AG, Yang H, Kawaguchi I. An economic evaluation of Risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. J Dermatolog Treat. 2022;33(1):229\u201339. Epub 2020 Apr 17. PMID: 32178555.","journal-title":"J Dermatolog Treat"},{"key":"504_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40274-021-08124-0","volume":"890","author":"Adalimumab biosimilar cost effective first-line treatment for psoriasis","year":"2021","unstructured":"Adalimumab biosimilar cost effective first-line treatment for psoriasis. PharmacoEcon Outcomes News. 2021;890:1. https:\/\/doi.org\/10.1007\/s40274-021-08124-0.","journal-title":"PharmacoEcon Outcomes News"},{"key":"504_CR38","doi-asserted-by":"crossref","unstructured":"AlRuthia Y, et al. COVID-19 and Saudi Arabia public financing of prescription Drugs: an opportunity for reform. Elsevier; 2021. pp. 3\u20136.","DOI":"10.1016\/j.hlpt.2020.10.008"},{"key":"504_CR39","doi-asserted-by":"publisher","unstructured":"Chowdhury S, Mok D, Leenen L. Transformation of health care and the new model of care in Saudi Arabia: Kingdom\u2019s Vision 2030. J Med Life. 2021 May-Jun;14(3):347\u201354. https:\/\/doi.org\/10.25122\/jml-2021-0070. PMID: 34377200; PMCID: PMC8321618.","DOI":"10.25122\/jml-2021-0070"},{"key":"504_CR40","doi-asserted-by":"crossref","unstructured":"Al-Jedai AH, Lomas J, Almudaiheem HY, Al-Ruthia YSH, Alghamdi S, Awad N, Alghamdi A, Alowairdhi MA, Alabdulkarim H, Almadi M, Bunyan RF, Ochalek J. Informing a cost-effectiveness threshold for Saudi Arabia. J Med Econ. 2023 Jan-Dec;26(1):128\u2013138. doi: 10.1080\/13696998.2022.2157141. PMID: 36576804.","DOI":"10.1080\/13696998.2022.2157141"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-023-00504-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-023-00504-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-023-00504-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T01:04:33Z","timestamp":1702083873000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-023-00504-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1186\/s12962-023-00504-1","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research project has been approved by the institutional review boards of the King Saud University Medical City (Project no. E-20-5644) in Riyadh, Saudi Arabia, and King Fahd Armed Force Hospital (REC 501) in Jeddah, Saudi Arabia. No written consent was required since no primary data were collected and the research was based on data retrieved from electronic medical records. The data were handled based on the ethical principles of the Helsinki declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}